查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553457

失眠治療藥物市場規模、佔有率、趨勢分析報告：按類型、銷售管道、地區、細分市場預測，2024-2030

Insomnia Therapeutics Market Size, Share & Trends Analysis Report By Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

失眠治療藥物市場成長與趨勢：

根據Grand View Research, Inc.的最新報告，預計2030年全球失眠治療市場將達到37.4億美元，2024年至2030年複合年成長率為4.4%。

這個市場主要是由取得專利的分子的存在、潛在的臨床候選藥物、不斷上升的壓力水平以及越來越多的難以入睡的老年人口推動的。失眠盛行率的增加、對該疾病的認知以及更安全藥物的供應預計將推動收益成長。

據估計，失眠症影響著世界上約 35% 的人口。這種症狀的不同模式包括難以開始和維持睡眠，通常伴隨頻繁和早醒，以及難以恢復睡眠。長期失眠會干擾日常生活，導致工作效率低落。如果不及時治療，這種情況可能會導致嚴重的憂鬱症和神經衰弱。

影響失眠治療藥物市場成長的因素包括壓力水平上升、市場上專利分子的存在、臨床管道中的潛在藥物、技術先進的醫療設備的引進以及老年人口的增加等。人們對睡眠不足對日常生活影響的認知不斷提高，預計將提高各種失眠治療方法的採用率，從而導致失眠治療市場的收益成長。

目前，廣泛用於治療失眠的藥物包括非苯二氮非專利藥物和抗憂鬱症，儘管市面上也有Orexin拮抗劑和褪黑激素拮抗劑等新藥。Eisai推出 lemborexant 預計將解決該領域未滿足的醫療需求，並在預測期內推動市場成長。根據2015年聯合國報告，到2030年，60歲及以上的人口預計將增加56%，達到約14億。這些統計數據表明，人口老化正在加劇。由於該族群更容易睡眠不足，因此對失眠治療藥物的需求預計會增加。

失眠治療藥物市場報告亮點

  • 苯二氮平類藥物佔據市場主導地位，2023 年市場佔有率為 28.9%。苯二氮平類藥物可用於治療與急性壓力相關的失眠。
  • 由於失眠患者的增加，非處方藥在 2023 年佔據最大的市場收益佔有率，為 61.4%。
  • 北美失眠治療藥物市場佔主導地位，2023年市場佔有率為35.4%。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 失眠治療藥物的變因、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 失眠治療分析工具
    • 波特的分析
    • PESTEL分析

第4章失眠治療藥物市場：按類型估計和趨勢分析

  • 細分儀表板
  • 失眠治療藥物市場：類型變異分析，2023 年和 2030 年
  • 苯二氮平類
  • 非苯二氮平類藥物
  • 抗憂鬱症
  • Orexin拮抗劑
  • 褪黑激素拮抗劑
  • 其他

第5章失眠治療藥物市場：依銷售管道估算及趨勢分析

  • 細分儀表板
  • 失眠治療藥物市場：2023年及2030年銷售管道波動分析
  • 處方箋
  • OTC

第6章 失眠治療藥物市場：區域估計與趨勢分析

  • 2023 年和 2030 年按地區分類的失眠藥物佔有率
  • 北美洲
    • 北美失眠藥物估計與預測，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030 年歐洲失眠藥物估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030 年亞太地區失眠藥物估計與預測
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲失眠藥物估計與預測，2018-2030 年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030 年中東和非洲失眠藥物估計和預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Takeda Pharmaceutical Company Ltd.
    • Vanda Pharmaceuticals
    • Merck &Co., Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mylan NV
    • Sumitomo Dainippon Pharma Co., Ltd
    • Sanofi
    • Paratek Pharmaceuticals Inc.
    • Ebb Therapeutics
簡介目錄
Product Code: GVR-2-68038-213-6

Insomnia Therapeutics Market Growth & Trends:

The global insomnia therapeutics market is expected to reach USD 3.74 billion by 2030, expanding at a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the presence of patented molecules, potential clinical pipeline candidates, rising stress level, and increase in geriatric population who find it difficult to fall asleep. Increase in prevalence of insomnia & awareness about this condition and availability of safer drugs are anticipated to fuel revenue growth.

Insomnia is estimated to affect approximately 35% of the global population. Different patterns of the condition include difficulty in sleep initiation and maintenance, which is generally accompanied with frequent awakenings & awakening too early with trouble sleeping again. Long-term insomnia can hamper everyday life, which may result in nonproductive work hours. If left untreated, this condition may lead to severe depression and nervous breakdown of the patient.

Factors influencing insomnia therapeutics market growth include rising stress level, presence of patented molecules in the market, potential drugs in clinical pipeline, introduction of technologically advanced medical devices, and growing geriatric population. Growing awareness about the impact of sleep deprivation on everyday life is anticipated to increase adoption rate of various treatments for insomnia, which is expected to lead to revenue growth of the insomnia therapeutics market.

Currently, widely adopted treatment options for insomnia include generic nonbenzodiazepines and antidepressants even though other novel agents such as orexin antagonists and melatonin antagonists are available in the market. Launch of Eisai's Lemborexant is expected to cater to unmet medical needs in this segment and fuel growth of this market over the forecast period. According to United Nations (UN) report in 2015, population in the age group of 60 years and above is projected to grow by 56% and is expected to reach around 1.4 billion by 2030. These statistics indicate the growing geriatric population. Since this population base is more susceptible to sleep deprivation, the demand for insomnia therapeutics is anticipated to increase.

Insomnia Therapeutics Market Report Highlights:

  • Benzodiazepines dominated the market and accounted for a market share of 28.9% in 2023. Benzodiazepines are useful for insomnia associated with acute stress.
  • Over-the-counter accounted for the largest market revenue share of 61.4% in 2023, owing to the increasing number of patients with insomnia.
  • The North America insomnia therapeutics market dominated the market in 2023 with a market share of 35.4%.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Insomnia Therapeutics Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Insomnia Therapeutics Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Insomnia Therapeutics Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Insomnia Therapeutics Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Benzodiazepines
    • 4.3.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Nonbenzodiazepines
    • 4.4.1. Nonbenzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Antidepressants
    • 4.5.1. Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Orexin Antagonists
    • 4.6.1. Orexin Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Melatonin Antagonists
    • 4.7.1. Melatonin Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Insomnia Therapeutics Market: Sales Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Insomnia Therapeutics Market: Sales Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Prescription
    • 5.3.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Over-the Counter
    • 5.4.1. Over-the Counter Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Insomnia Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Insomnia Therapeutics Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. U.K.
      • 6.3.2.1. U.K. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Sweden Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. China Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Thailand
      • 6.4.6.1. Thailand Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Insomnia Therapeutics and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Insomnia Therapeutics Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Takeda Pharmaceutical Company Ltd.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Vanda Pharmaceuticals
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Merck & Co., Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Pfizer Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Teva Pharmaceutical Industries Ltd.
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Mylan N.V.
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Sumitomo Dainippon Pharma Co., Ltd
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Sanofi
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Paratek Pharmaceuticals Inc.
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Ebb Therapeutics
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives